Ally Bridge led a $140m Series B round in Shoreline Biosciences, a biotechnology company. Additional investors included Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, Boxer Capital, BVF Partners, LP, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Gilead, Stork Capital and Wedbush Healthcare Partners. “We are proud of Shoreline’s tremendous progress over the past year, including next generation, more persistent and more effective iPSC-derived NK cells, enhancing our core technologies, advancing our preclinical programs, establishing transformative and validating partnerships with Kite and BeiGene, creating smart manufacturing methods, and attracting exceptional talent to support our next phase of development and growth. With this financing and our corporate partnerships, Shoreline has now more than $300m to continue building our pipeline of safe, effective and affordable cellular immunotherapies for both solid tumors and hematologic malignancies," Kleanthis Xanthopoulos, Shoreline Co-Founder, Chairman and CEO.